6-(4-Methoxyphenoxy)hexanal | 1383151-90-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 6-(4-Methoxyphenoxy)hexanal
• CAS: 1383151-90-3
• 化学式: C₁₃H₁₈O₃
• 分子量: 222.284
• InChiKey: FLABSJTWPUJHPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(4-Methoxyphenoxy)hexanal 在 1,2-bis(dimethylsilyl)ethane 、 三(五氟苯基)硼烷 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以61%的产率得到1-(hexyloxy)-4-methoxybenzene
  参考文献：
  名称：

  由B（C醚取代的醇与羰基化合物的化学选择性脱氧6 ˚F 5）3 -催化还原（HME 2 SICH 2）2 †

  摘要：

  使用（HMe 2 SiCH 2）2作为还原剂，开发了B（C 6 F 5）3催化的醚取代的醇和羰基化合物的脱氧反应。这种独特的试剂显示出优于传统的以硅为中心的氢硅烷的独特优势，可高收率地提供相应的烷烃，并对醚，芳基卤化物和烯烃具有良好的耐受性。对照实验表明（HMe 2 SiCH 2）2可能以分子内Si / O活化方式促进该方法。

  DOI：

  10.1039/c8cc01163j
• 作为产物：
  描述：

  4-甲氧基苯酚 在 碳酸氢钠 、 potassium carbonate 、 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 6-(4-Methoxyphenoxy)hexanal
  参考文献：
  名称：

  由B（C醚取代的醇与羰基化合物的化学选择性脱氧6 ˚F 5）3 -催化还原（HME 2 SICH 2）2 †

  摘要：

  使用（HMe 2 SiCH 2）2作为还原剂，开发了B（C 6 F 5）3催化的醚取代的醇和羰基化合物的脱氧反应。这种独特的试剂显示出优于传统的以硅为中心的氢硅烷的独特优势，可高收率地提供相应的烷烃，并对醚，芳基卤化物和烯烃具有良好的耐受性。对照实验表明（HMe 2 SiCH 2）2可能以分子内Si / O活化方式促进该方法。

  DOI：

  10.1039/c8cc01163j

文献信息

• Design and Synthesis of Pironetin Analogue/Combretastatin A-4 Hybrids and Evaluation of Their Cytotoxic Activity
  作者：Sandra Torijano-Gutiérrez、Concepción Vilanova、Santiago Díaz-Oltra、Juan Murga、Eva Falomir、Miguel Carda、J. Alberto Marco

  DOI：10.1002/ejoc.201301725

  日期：2014.4

  describe the preparation of a series of hybrid molecules containing a combretastatin A-4 moiety and a pironetin analogue fragment linked by an ester spacer of variable length. The cytotoxic activities of these compounds have been measured and the relationship between the structure and cytotoxicity is discussed. Some of the tested compounds showed cytotoxicity values of the same order of magnitude as

  我们描述了一系列混合分子的制备，该分子包含由可变长度的酯间隔物连接的 Combretastatin A-4 部分和 pironetin 类似物片段。已经测量了这些化合物的细胞毒活性，并讨论了结构和细胞毒性之间的关系。一些测试化合物显示出与母体分子考布他汀 A-4 和 pironetin 相同数量级的细胞毒性值，并且对正常细胞的毒性低于后者。
• Design, Synthesis, and Biological Evaluation of <i>N</i>-Alkylated Deoxynojirimycin (DNJ) Derivatives for the Treatment of Dengue Virus Infection
  作者：Wenquan Yu、Tina Gill、Lijuan Wang、Yanming Du、Hong Ye、Xiaowang Qu、Ju-Tao Guo、Andrea Cuconati、Kang Zhao、Timothy M. Block、Xiaodong Xu、Jinhong Chang

  DOI：10.1021/jm300171v

  日期：2012.7.12

  We recently described the discovery of oxygenated N-alkyl deoxynojirimycin (DNJ) derivative 7 (CM-10-18) with antiviral activity against dengue virus (DENY) infection both in vitro and in vivo. This imino sugar was promising but had an EC50 against DENY in BHK cells of 6.5 mu M, which limited its use in in vivo. Compound 7 presented structural opportunities for activity relationship analysis, which we exploited and report here. These structure activity relationship studies led to analogues 2h, 2l, 3j, 3l, 3v, and 4b-4c with nanomolar antiviral activity (EC50 = 0.3-0.5 mu M) against DENY infection, while maintaining low cytotoxicity (CC50 > 500 mu M, SI > 1000). In male Sprague-Dawley rats, compound 3l was well tolerated at a dose up to 200 mg/kg and displayed desirable PK profiles, with significantly improved bioavailability (F = 92 +/- 4%).
• GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE
  申请人：Genzyme Corporation

  公开号：EP2320886B1

  公开（公告）日：2017-06-28
• 2-acylaminopropanol-type glucosylceramide synthase inhibitors
  申请人：Genzyme Corporation

  公开号：EP2594563B1

  公开（公告）日：2018-07-18
• 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
  申请人：Genzyme Corporation

  公开号：US20180093981A1

  公开（公告）日：2018-04-05

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.